420 related articles for article (PubMed ID: 26456234)
1. Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis.
Koibuchi K; Miyagi M; Arai T; Aoki T; Aikawa A; Sakai K
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():22-8. PubMed ID: 26456234
[TBL] [Abstract][Full Text] [Related]
2. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
3. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
4. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
[TBL] [Abstract][Full Text] [Related]
5. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
[TBL] [Abstract][Full Text] [Related]
6. A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation.
Oka S; Obata Y; Torigoe K; Torigoe M; Abe S; Muta K; Ota Y; Kitamura M; Kawasaki S; Hirose M; Uramatsu T; Yamashita H; Arai H; Mukae H; Nishino T
Drugs R D; 2017 Sep; 17(3):389-396. PubMed ID: 28547536
[TBL] [Abstract][Full Text] [Related]
7. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
[TBL] [Abstract][Full Text] [Related]
8. Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage.
Furukawa T; Okada K; Abe M; Tei R; Oikawa O; Maruyama N; Maruyama T
Int J Mol Sci; 2015 Dec; 16(12):30181-9. PubMed ID: 26694377
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
[TBL] [Abstract][Full Text] [Related]
10. Effects of Long-Term Erythropoiesis-Stimulating Agents on Iron Metabolism in Patients on Hemodialysis.
Onuma S; Honda H; Kobayashi Y; Yamamoto T; Michihata T; Shibagaki K; Yuza T; Hirao K; Tomosugi N; Shibata T
Ther Apher Dial; 2015 Dec; 19(6):582-9. PubMed ID: 26481900
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of benefits to non-dialysis CKD patients between darbepoetin alpha and epoetin beta pegol].
Ito C; Akimoto T; Morishita Y; Yamamoto H; Ogura M; Yamazaki T; Miki A; Homma S; Kusano E; Asano Y; Nagata D
Nihon Jinzo Gakkai Shi; 2015; 57(7):1233-40. PubMed ID: 26665615
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
[TBL] [Abstract][Full Text] [Related]
14. CERA conversion to darbepoetin alfa in 154 hemodialysis patients.
Dimitrov Y; Rieger J; Krummel T; Petitjean P; Klein A; Chantrel F; Meyer N; Hannedouche T
Int Urol Nephrol; 2020 Oct; 52(10):1979-1985. PubMed ID: 32725508
[TBL] [Abstract][Full Text] [Related]
15. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study.
Galle JC; Claes K; Kiss I; Winearls CG; Herlitz H; Guerin A; Di Giulio S; Suranyi MG; Bridges I; Addison J; Farouk M
Nephrol Dial Transplant; 2012 Jun; 27(6):2303-11. PubMed ID: 22140136
[TBL] [Abstract][Full Text] [Related]
16. Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials.
Tsuruya K; Uemura Y; Hirakata H; Kitazono T; Tsubakihara Y; Suzuki M; Ohashi Y
Nephrology (Carlton); 2017 Oct; 22(10):769-775. PubMed ID: 27312361
[TBL] [Abstract][Full Text] [Related]
17. A single arm, prospective, open label, multicentre study for evaluation of efficacy and safety of IV CERA for treatment of chronic renal anaemia in dialysis patients not currently treated with ESA.
Nainan GK; Pathak VR; Dalal SS; Saxena S; Mittal D; Raju TR; Gokulnath ; Isaac R; Rajapurkar MM; Rana DS; Shah BV; Ray DS; Thiagarajan CM; Jha RM; Kukreja AA; Pophale RR
J Assoc Physicians India; 2014 Mar; 62(3):232-6. PubMed ID: 25327065
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis.
Escudero-Vilaplana V; Martínez-Nieto C; López-Gómez JM; Vega-Martínez A; Bellón-Cano JM; Sanjurjo-Sáez M
Int J Clin Pharm; 2013 Jun; 35(3):463-8. PubMed ID: 23595914
[TBL] [Abstract][Full Text] [Related]
20. Possible role of neocytolysis in anemia in hemodialysis patients with darbepoetin alfa or continuous erythropoietin receptor activator.
Daimon S
Ther Apher Dial; 2020 Oct; 24(5):602-606. PubMed ID: 32537874
[No Abstract] [Full Text] [Related]
[Next] [New Search]
